암치료용 유전체학 : 시장 점유율 분석, 산업 동향 및 통계 데이터, 성장 예측(2026-2031년)

According to Mordor Intelligence, genomics in the cancer care market size in 2026 is estimated at USD 28.44 billion, growing from 2025 value of USD 24.5 billion with 2031 projections showing USD 59.78 billion, growing at 16.05% CAGR over 2026-2031.

This report is Segmented by Product Type (Instruments, Consumables, and Services), Technology (PCR, Microarrays, Genome Sequencing, and More), Application (Diagnostics, Drug Discovery & Clinical Trials Genomics, and More), End-User (Hospitals and Cancer Centres, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Global Genomics In Cancer Care Market Trends and Insights

Growing Burden of Cancer & Earlier Screening Programs

Robust growth in global cancer incidence is compelling health-system planners to shift resources toward preventive genomic screening. Latin America alone projects a 66% rise in cancer cases by 2040, intensifying pressure to catch malignancies at sub-clinical stages. U.S. agencies embraced blood-based detection when the FDA cleared Guardant Health's Shield test for colorectal screening in adults aged 45 and older, setting a precedent for non-invasive assays. Large population trials such as the National Cancer Institute's Vanguard study employ the same platform to test multi-cancer detection across diverse cohorts. These developments create long-term reimbursement pathways, foster payer confidence, and bolster recurring revenue streams for test developers while lowering downstream treatment costs.

Increasing Adoption Of NGS-Based Comprehensive Genomic Profiling

Oncology practices are migrating from sequential single-gene tests toward expansive panels that interrogate hundreds of loci in one run. Evidence from the GOZILA trial showed patients guided by the Guardant360 CDx liquid biopsy achieved a median overall survival of 18.6 months compared with 9.9 months under standard care. Illumina's TruSight Oncology Comprehensive became the first FDA-cleared kit with pan-cancer companion-diagnostic claims. Coupled with AI analytics, laboratories now deliver clinically actionable reports within days, and U.S. Medicare increasingly reimburses broad panels over iterative assays, accelerating mainstream uptake.

Shortage Of Accredited Molecular Pathologists

Worldwide demand for professionals who can translate multi-omic data into clinical action far exceeds supply. Training requirements encompass molecular biology, bioinformatics, and oncology subspecialties, competencies that extend beyond legacy pathology curricula. Emerging economies face added challenges as talent migrates to higher-income regions. AI tools lighten routine interpretation workloads, yet regulations still require board-certified oversight for final sign-off. Fast-track certification programs are under development, but workforce expansion will lag market growth for several years.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Cost Decline of Sequencing & Digital PCR Reagents
2. Scaling Liquid-Biopsy Pipelines for Minimal-Residual-Disease (MRD) Monitoring
3. Persistently High Total-Cost-Of-Ownership for WGS Platforms

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Instruments represented the largest revenue pool, holding 37.80% share of the genomics in the cancer care market in 2025. Demand reflected ongoing platform refresh cycles as users swapped legacy sequencers for higher-throughput, longer-read systems. Consumables sales expanded in line with test-volume growth, while point-of-care cartridges opened new, decentralized channels.

Services are accelerating at an 18.35% CAGR, underscoring a shift toward data interpretation, cloud analytics, and integrated clinical reporting. Guardant Health's 31% revenue jump to USD 737 million during 2024 shows the pull of recurring testing and bioinformatics fees. Hospitals increasingly outsource bioinformatics to mitigate staffing shortages, and bundled, end-to-end service contracts now cover sample logistics, sequencing, interpretation, and decision-support updates. This evolution positions service providers as strategic partners rather than transactional suppliers within the genomics in cancer care market.

Genome sequencing platforms based on short-read NGS secured 45.70% market share in 2025, supported by established laboratory workflows and extensive clinical evidence. Yet single-molecule, real-time sequencing is expanding at a startling 22.85% CAGR as oncologists seek structural-variant resolution in repeat-rich regions and methylation layers unavailable from short reads.

Oxford Nanopore's latest chemistry generated complete chromosome assemblies and simultaneous epigenetic maps, demonstrating the clinical readiness of long-read approaches. Meanwhile, Roche's sequencing-by-expansion prototypes promise to merge long reads with high throughput, threatening to redraw product-replacement cycles. PCR-based kits retain value for low-plex companion diagnostics and rapid EGFR or KRAS checks, yet microarrays are ceding ground as sequencing prices near parity. Technology diversity ensures that laboratories can align platform choice with specific oncology use cases inside the genomics in cancer care market.

Complete Report Scope:

• By Product Type
  • Instruments
  • Consumables
  • Services
• By Technology
  • Genome Sequencing
  • PCR
  • Microarrays &
  • Others
• By Application
  • Diagnostics
  • Drug Discovery & Clinical Trials Genomics
  • Personalized / Precision Oncology
  • Others
• By End-user
  • Hospitals & Cancer Centres
  • Reference & Clinical Laboratories
  • Pharmaceutical & Biotech Companies
  • Academic & Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led with 36.60% market share in 2025, supported by broad payer coverage, a mature clinical-trial network, and stringent but predictable regulatory oversight. The FDA's May 2024 Laboratory Developed Tests final rule aligned quality requirements across commercial and academic laboratories. Parallel Medicare decisions extended reimbursement to liquid-biopsy-based MRD surveillance, unlocking sizable, recurring test volumes. Cross-industry collaborations ensure rapid migration of research innovations into front-line clinical practice, consolidating the region's leadership in the genomics in cancer care market.

Asia Pacific records the fastest regional CAGR at 14.55% to 2031. National genome programs in China, Japan, Singapore, and the United Arab Emirates underpin large-scale sequencing infrastructure and create fertile ground for early screening pilots. Ongoing investment in Saudi Arabia's precision-medicine corridor, combined with streamlined regulatory pathways in the United Arab Emirates, attracts multinational diagnostics firms to establish regional hubs. Rising cancer incidence and widening insurance coverage accelerate demand, while local manufacturing partnerships drive down consumables' costs, improving accessibility.

Europe remains a critical pillar of global adoption through coordinated regulatory and value-assessment frameworks. The European Commission's conditional approval of Illumina's divestment plan for GRAIL removed a legal logjam, restoring competitive balance and allowing pan-European multi-cancer screening pilots to proceed. Meanwhile, the EU In Vitro Diagnostic Regulation enforces stringent clinical-evidence requirements, boosting confidence among physicians and payers. Standard-setting bodies such as the European Liquid Biopsy Society publish harmonized protocols that foster reproducibility across laboratories. In combination, these measures sustain healthy growth despite mature infrastructure.

1. Illumina
2. Thermo Fisher Scientific
3. Roche
4. Agilent Technologies
5. QIAGEN
6. Pacific Bioscience
7. Guardant Health
8. Exact Sciences
9. Foundation Medicine Inc.
10. Oxford Nanopore Technologies plc
11. Myriad Genetics
12. Bio-Rad Laboratories
13. GE HealthCare Technologies Inc.
14. PerkinElmer
15. BGI Genomics Co. Ltd.
16. Adaptive Biotechnologies Corp.
17. Personalis Inc.
18. Invitae
19. 10x Genomics Inc.
20. Burning Rock Biotech Ltd.
21. Natera

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Burden Of Cancer & Earlier Screening Programs
  • 4.2.2 Increasing Adoption Of NGS-Based Comprehensive Genomic Profiling
  • 4.2.3 Rapid Cost Decline Of Sequencing & Digital PCR Reagents
  • 4.2.4 Scaling Liquid-Biopsy Pipelines For Minimal-Residual-Disease (MRD) Monitoring
  • 4.2.5 AI-Powered Multi-Omic Decision-Support Tools For Oncologists
  • 4.2.6 Rise Of Reimbursement For Tumor-Agnostic Companion Diagnostics
• 4.3 Market Restraints
  • 4.3.1 Shortage Of Accredited Molecular Pathologists
  • 4.3.2 Persistently High Total-Cost-Of-Ownership For WGS Platforms
  • 4.3.3 Cyber-Security & Genomic-Data-Sovereignty Regulation
  • 4.3.4 Limited Clinical-Utility Evidence For Emerging MRD Assays
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Product Type
  • 5.1.1 Instruments
  • 5.1.2 Consumables
  • 5.1.3 Services
• 5.2 By Technology
  • 5.2.1 Genome Sequencing
  • 5.2.2 PCR
  • 5.2.3 Microarrays &
  • 5.2.4 Others
• 5.3 By Application
  • 5.3.1 Diagnostics
  • 5.3.2 Drug Discovery & Clinical Trials Genomics
  • 5.3.3 Personalized / Precision Oncology
  • 5.3.4 Others
• 5.4 By End-user
  • 5.4.1 Hospitals & Cancer Centres
  • 5.4.2 Reference & Clinical Laboratories
  • 5.4.3 Pharmaceutical & Biotech Companies
  • 5.4.4 Academic & Research Institutes
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Illumina Inc.
  • 6.3.2 Thermo Fisher Scientific Inc.
  • 6.3.3 F. Hoffmann-La Roche AG
  • 6.3.4 Agilent Technologies Inc.
  • 6.3.5 QIAGEN NV
  • 6.3.6 Pacific Biosciences of California Inc.
  • 6.3.7 Guardant Health Inc.
  • 6.3.8 Exact Sciences Corporation
  • 6.3.9 Foundation Medicine Inc.
  • 6.3.10 Oxford Nanopore Technologies plc
  • 6.3.11 Myriad Genetics Inc.
  • 6.3.12 Bio-Rad Laboratories Inc.
  • 6.3.13 GE HealthCare Technologies Inc.
  • 6.3.14 PerkinElmer Inc.
  • 6.3.15 BGI Genomics Co. Ltd.
  • 6.3.16 Adaptive Biotechnologies Corp.
  • 6.3.17 Personalis Inc.
  • 6.3.18 Invitae Corporation
  • 6.3.19 10x Genomics Inc.
  • 6.3.20 Burning Rock Biotech Ltd.
  • 6.3.21 Natera Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment